Semi-retired. 40 years experience in biotech industry, as scientist, inventor, research director, consultant, expert witness, and Board of Directors member, as well as long time investor in biotech, including private equity, LLCs, and joint ventures. Currently, Expert Consultant in biotechnology, intellectual property, patents, molecular genetics, genomics, RNA silencing, RNA interference, epigenetics, bioinformatics and cyber infrastructure. Professor Emeritus at University of Arizona.
Long / short equities. Bonds /option trading/ commodities; Equity analyst, farmer, property management and RE development.
"The illusion [....] will continue as long as it's profitable to continue the illusion. At the point where the illusion becomes too expensive to maintain, they will just take down the scenery, they will pull back the curtains, they will move the tables and chairs out of the way and you will see the brick wall at the back of the theater."
- Frank Zappa
Founded by Dr. Hung Tran, MD, MS, CNPR, (in collaboration with Dr. Tran BioSci analyst, Ngoc Vu, and other PhDs), Integrated BioSci Investing (“IBI) marketplace research is delivering robust returns since inception. To name a couple winners, Nektar Therapeutics and Spectrum Pharmaceuticals delivered profits of 446% and 196% for our subscribers, respectively. Our secret sauce is extreme due diligence coupled with expert data analysis. The service features a once-weekly exclusive in-depth Integrated BioSci article (in the form of research, reports, or interviews), daily individual stocks consulting, and model portfolios. Of note, we’ll increase our price soon (SUBSCRIBE to IBI now to lock in the current price and save money). Click the orange FOLLOW button to receive the FREE real-time alerts on our articles and blogs. To read the FREE once-weekly articles covering promising small-cap bioscience firms, check out www.drtranbiosci.com (and make sure to register for our mailing list). You can read up on Dr. Tran’s background in an in-depth article by following this link. http://www.drtranbiosci.com/p/dr-tran.html "Stellar therapeutics for patients. Differentiated intelligence for investors. Premium valuations for firms."
9/2016. looks like growth in technology ( the cloud, artificial intelligence,self driving cars, VR, data cntrs) will continue to drive AVGO, NVDA, QCOM higher, but the best developing opportunity may be in eReits, as rates go up, many will find themselves under water on buys the last few yrs. On health care, while it would be hard to get a cap on drug prices through congress, a decrease in benefits via medicare and ACA, will accomplish the same thing, by giving people less to spend, so I am not interested in any new health care purchases, no matter what the story.